Logo image of ZGNX

ZOGENIX INC (ZGNX) Stock Fundamental Analysis

NASDAQ:ZGNX - Nasdaq - Common Stock

26.68  +0.42 (+1.6%)

After market: 26.69 +0.01 (+0.04%)

Fundamental Rating

2

Taking everything into account, ZGNX scores 2 out of 10 in our fundamental rating. ZGNX was compared to 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ZGNX have multiple concerns. ZGNX shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ZGNX had negative earnings in the past year.
ZGNX Yearly Net Income VS EBIT VS OCF VS FCFZGNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 -100M -200M -300M -400M

1.2 Ratios

Industry RankSector Rank
ROA -48.54%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZGNX Yearly ROA, ROE, ROICZGNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 -50 -100 -150

1.3 Margins

Industry RankSector Rank
OM -274.33%
PM (TTM) -278.4%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZGNX Yearly Profit, Operating, Gross MarginsZGNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

ZGNX has more shares outstanding than it did 1 year ago.
ZGNX has a worse debt/assets ratio than last year.
ZGNX Yearly Shares OutstandingZGNX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M 50M
ZGNX Yearly Total Debt VS Total AssetsZGNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M

2.2 Solvency

ZGNX has an Altman-Z score of -2.21. This is a bad value and indicates that ZGNX is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 0.88 indicates that ZGNX is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF N/A
Altman-Z -2.21
ROIC/WACCN/A
WACCN/A
ZGNX Yearly LT Debt VS Equity VS FCFZGNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 200M 400M

2.3 Liquidity

A Current Ratio of 3.63 indicates that ZGNX has no problem at all paying its short term obligations.
ZGNX has a Quick Ratio of 3.57. This indicates that ZGNX is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 3.63
Quick Ratio 3.57
ZGNX Yearly Current Assets VS Current LiabilitesZGNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M 400M 500M

More info and screens

7

3. Growth

3.1 Past

ZGNX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.99%.
ZGNX shows a strong growth in Revenue. In the last year, the Revenue has grown by 498.88%.
The Revenue has been growing by 23.14% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-5.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)498.88%
Revenue growth 3Y11.58%
Revenue growth 5Y23.14%
Sales Q2Q%213.04%

3.2 Future

The Earnings Per Share is expected to grow by 12.86% on average over the next years. This is quite good.
ZGNX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 103.02% yearly.
EPS Next Y26.75%
EPS Next 2Y35.4%
EPS Next 3Y20.54%
EPS Next 5Y12.86%
Revenue Next Year113.18%
Revenue Next 2Y103.93%
Revenue Next 3Y102.65%
Revenue Next 5Y103.02%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ZGNX Yearly Revenue VS EstimatesZGNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 500M 1B
ZGNX Yearly EPS VS EstimatesZGNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2 -4 -6 -8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZGNX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZGNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZGNX Price Earnings VS Forward Price EarningsZGNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -6.29
ZGNX Per share dataZGNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as ZGNX's earnings are expected to grow with 20.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.4%
EPS Next 3Y20.54%

More info and screens

0

5. Dividend

5.1 Amount

ZGNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZOGENIX INC

NASDAQ:ZGNX (3/4/2022, 8:10:11 PM)

After market: 26.69 +0.01 (+0.04%)

26.68

+0.42 (+1.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)05-04 2022-05-04
Inst Owners0.83%
Inst Owner Change0%
Ins Owners1.56%
Ins Owner Change0%
Market Cap1.49B
Analysts73.33
Price Target37.3 (39.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.29
P/FCF N/A
P/OCF N/A
P/B 8.35
P/tB N/A
EV/EBITDA -6.29
EPS(TTM)-4.07
EYN/A
EPS(NY)-2.98
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.46
BVpS3.2
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.54%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -274.33%
PM (TTM) -278.4%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.63
Quick Ratio 3.57
Altman-Z -2.21
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y26.75%
EPS Next 2Y35.4%
EPS Next 3Y20.54%
EPS Next 5Y12.86%
Revenue 1Y (TTM)498.88%
Revenue growth 3Y11.58%
Revenue growth 5Y23.14%
Sales Q2Q%213.04%
Revenue Next Year113.18%
Revenue Next 2Y103.93%
Revenue Next 3Y102.65%
Revenue Next 5Y103.02%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A